Merck KGaA suffers setback for cancer drug

German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.

Merck said in a statement it had decided to "voluntarily withdraw the marketing authorisation application to the European Medicines Agency" for to be used to treat patients with advanced or metastatic non-small cell lung cancer.

The decision was "based on feedback from European regulatory authorities, indicating that further data would be required," the statement said.

It would not affect, however, "the proven utility of Erbitux in its already approved indications in metastatic and ," Merck insisted.

"We are disappointed that we have not been able to move forward with the filing but it has become apparent that further data will be required to support the clinical utility of Erbitux in this specific population," said Merck's head of drug development, Annalisa Jenkins.

Already in July, Merck KGaA had said that phase III clinical trials of Erbitux for treatment of drug had shown no benefits of the drug for patients.

The news hit Merck KGaA shares which were showing a loss of 1.24 percent at 93.67 euros in mid-morning trade on the Frankfurt stock exchange in a generally softer market.

add to favorites email to friend print save as pdf

Related Stories

Merck KGaA suffers setback on cancer drug

Jul 05, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Merck says US rejects its MS drug

Mar 02, 2011

German pharmaceutical group Merck KgaA said Wednesday that the US Food and Drug Administration (FDA) has refused to approve use of its multiple sclerosis treatment Cladribine.

Facebook sidelines contested Merck profile page

Nov 29, 2011

Facebook will sideline a Merck page at the social network until a pair of US and German companies work out which one gets the online address, a source familiar with the matter told AFP.

Recommended for you

Britain to map 100,000 DNA code sequences

2 hours ago

British scientists are to map 100,000 complete DNA code sequences in a project that will make the country a world leader in genetic research on cancer and rare diseases, the prime minister said on Friday.

New paper describes how DNA avoids damage from UV light

16 hours ago

In the same week that the U.S. surgeon general issued a 101-page report about the dangers of skin cancer, researchers at Montana State University published a paper breaking new ground on how DNA – the genetic code in every ...

User comments